The Median Effective Dose and Bispectral Index of Remimazolam Tosilate for Anesthesia Induction in Elderly Patients: An Up-and-Down Sequential Allocation Trial
Miao Liu,Yuan Sun,Lingxue Zhou,Kunpeng Feng,Tianlong Wang,Xuexin Feng
DOI: https://doi.org/10.2147/CIA.S364222
IF: 3.829
2022-05-20
Clinical Interventions in Aging
Abstract:Miao Liu, 1– 3 Yuan Sun, 1– 3 Lingxue Zhou, 1– 3 Kunpeng Feng, 1– 3 Tianlong Wang, 1– 3 Xuexin Feng 1– 3 1 Department of Anesthesiology, Capital Medical University Xuanwu Hospital, Beijing, People's Republic of China; 2 Center for Sleep and Consciousness Disorders, Capital Medical University, Beijing, People's Republic of China; 3 Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, People's Republic of China Correspondence: Xuexin Feng, Department of Anesthesiology, Capital Medical University Xuanwu Hospital, No. 45 Changchun St., Xicheng District, Beijing, 100053, People's Republic of China, Tel +86-1083798277, Email Purpose: Remimazolam is a new type of ultrashort benzodiazepine drug with an unclear optimal dose for general anesthesia induction in elderly patients aged > 60 years. Therefore, this study aimed to determine the effective dose of remimazolam tosilate induction and explore its correlation with the bispectral index (BIS). Patients and Methods: A total of 42 elderly patients were divided into two age groups: 60– 69 (group A) and 70– 85 (group B) years. An initial dose of 0.1mg/kg(Group A) and 0.05 mg/kg(Group B) remimazolam tosilate was administered, and the Modified Observer's Assessment of Alertness/Sedation scale was used to assess adequate responses. The dose was calculated using the up-and-down allocation technique based on the previous response. The sequential formula and probit regression model were used to calculate ED50 and BIS50. ED95 was determined using the probit regression model. Results: The ED50 of remimazolam tosilate for anesthesia induction were 0.088 mg/kg (95% confidence interval [CI] 0.071– 0.108) and 0.061 mg/kg (95% CI 0.053– 0.069) in groups A and B, respectively. ED95 was 0.118 mg/kg (95% CI 0.103– 0.649) and 0.090 mg/kg (95% CI 0.075– 0.199) in groups A and B, respectively. The remimazolam tosilate administration could decrease BIS. BIS50 was 86.0 (95% CI 83.7– 88.6) and 85.4 (95% CI 84.1– 86.8) in groups A and B, respectively. Conclusion: During the induction process, patients' consciousness should be observed. The dose of remimazolam tosilate could be chosen after careful consideration of individual variations. Keywords: remimazolam, anesthesia induction, geriatric, up-and-down sequential allocation Remimazolam is a new type of ultrashort benzodiazepine drug that is increasingly applied in clinical anesthesia. Several previous studies reported that benzodiazepines have been confirmed to function as a gamma-aminobutyric acid-A (GABA-A) receptor in the amygdala and reticular activating system binding sites and to change the conformation of chloride channels, resulting in hyperpolarization that inhibits its effects in the central nervous system. 1,2 Midazolam was the classic benzodiazepine used for sedation and as an anticonvulsant since 1982. 3 However, the long-term use of midazolam is associated with disadvantages, namely, drug accumulation and prolonging sedation time. 4 Remimazolam is a midazolam derivative added with an ester moiety, and besylate and tosylate forms were developed. 5 It is metabolized by nonspecific tissue esterase enzymes, and the binding ability of its main metabolite CNS7054 to GABA-A receptor decreased significantly. 5 Studies have shown that its sedative effects can be quickly reversed by flumazenil. 6 The advantages of remimazolam include a fast onset of action, short recovery time, and stable hemodynamics. 1 Currently, a clinical study of remimazolam mainly focused on the induction and maintenance of non-elderly patients and endoscopic anesthesia. 7 The optimal doses required for general anesthesia induction in elderly patients aged >60 years remain unclear. The bispectral index (BIS) is a method used to monitor the hypnotic state, which has been demonstrated to correlate well with sedation levels following induction with propofol. The effect of remimazolam on BIS during induction in elderly patients is not completely understood. Therefore, this study aimed to determine the effective dose of remimazolam in elderly patients aged 60–85 years using a sequential design and Dixon up-and-down methods and to evaluate the effect of remimazolam on BIS scores. This study was registered in the Chinese Clinical Trial Registry (ChiCTR2100046482). Ethical approval was provided by the Ethics Committee of Capital Medical University, Beijing, China, on April 26, 2021 (No. [2021] 022). This study was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all patients who -Abstract Truncated-
geriatrics & gerontology,gerontology